APA (7th ed.) Citation

I, H., J, L., SW, K., & YC, S. (2025). Dual IL-2/IL-21 priming augments the anti-tumor function of CD16V-CAR/TRAIL-engineered NK cells in combination with monoclonal antibodies. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 189, 118289. https://doi.org/10.1016/j.biopha.2025.118289

Chicago Style (17th ed.) Citation

I, Hwang, Lee J, Kim SW, and Sung YC. "Dual IL-2/IL-21 Priming Augments the Anti-tumor Function of CD16V-CAR/TRAIL-engineered NK Cells in Combination with Monoclonal Antibodies." Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie 189 (2025): 118289. https://doi.org/10.1016/j.biopha.2025.118289.

MLA (9th ed.) Citation

I, Hwang, et al. "Dual IL-2/IL-21 Priming Augments the Anti-tumor Function of CD16V-CAR/TRAIL-engineered NK Cells in Combination with Monoclonal Antibodies." Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, vol. 189, 2025, p. 118289, https://doi.org/10.1016/j.biopha.2025.118289.